Deucravacitinib in Psoriasis Patients with a History of Malignancy: Follow-up after 4 Years of Deucravacitinib Treatment in the POETYK PSO Program. (2025). SKIN The Journal of Cutaneous Medicine, 9(2), s538. https://doi.org/10.25251/skin.10.supp.538